Dataset Information

The effect of propolis on anthropometric indices and lipid profile: a systematic review and meta-analysis of randomized controlled trials.

ABSTRACT:

Background & objectives

The current evidence base regarding the impact of propolis consumption on lipid profile in humans is equivocal. Thus, we sought to investigate the impact of propolis consumption on anthropometric indices and lipid profile in this meta-analysis.

Methods

Cochrane Library, Scopus, PubMed, and Web of Science electronic databases were searched up to December 2019. A random-effects model used to pool effect size. The leave-one-out method used to conduct sensitivity analysis.

Results

Five RCTs were included in this study. Our findings indicated a significant decrease in triglyceride (TG) (WMD: -3.91 mg/dl, 95% CI: -4.22, -3.60), and a significant increase in high-density lipoprotein (HDL) (WMD: 3.41 mg/dl, 95% CI: 0.05, 6.76), however, for body mass index, weight, cholesterol (CL), and low-density lipoprotein (LDL), no significant alterations were evident.

Conclusion

This study revealed that consumption of propolis is associated with a reduction in TG levels, in addition to an increase in HDL levels. Nevertheless, additional research is required to further delineate the relationship between propolis consumption and lipid profile.

SUBMITTER: Salehi-Sahlabadi A

PROVIDER: S-EPMC7843794 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:BACKGROUND: The effects of fish oil supplements on lipid profile in dialysis patients are controversial. With increasing interest in the potential health benefits of fish oil, it is important to explore its real effects. OBJECTIVE: We aimed to identify and quantify the effects of fish oil on triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) in dialysis patients. METHODS: PubMed, EMBASE and the Cochrane Central Register of Controlled Trials were searched for relevant trials of fish oil and lipid profile in dialysis patients. We identified 209 potential studies and included 13 randomized controlled trials. Eligible studies, determined by consensus using predefined criteria, were reviewed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and a meta-analysis was performed. RESULTS: Compared with the control group, serum TG and TC levels in the fish oil group were reduced by 0.23 mmol/L (95% CI, -0.31, -0.14, P <0.01) and 0.12 mmol/L (95% CI, -0.23, -0.01, P =0.03), respectively. HDL-C levels were increased by 0.20 mmol/L (95% CI, 0.01, 0.40, P <0.01) attributable to fish oil. In contrast, fish oil did not influence serum LDL-C levels. Subgroup analysis showed the effects of fish oil were stronger in subjects with higher baseline TG levels, and the long-term intervention (>12 w) demonstrated a tendency towards greater improvement of serum HDL-C and LDL-C levels compared with short-term intervention (?12 w). However, both of the changes were not statistically significant in meta-regression analysis. There were no obvious difference in effects of different doses and components of fish oil on lipid levels. CONCLUSION: Fish oil supplements reduced serum TG and TC levels, and increased HDL-C levels, without affecting LDL-C levels among dialysis patients. It should benefit patients at risk of cardiovascular diseases. Based on randomized controlled trials, we suggested a daily supplement dose of fish oil for dialysis patients of >1 g, but a high dose might not be necessary.